Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
about
Lipid-lowering agents for nephrotic syndromeLipoprotein(a) as a cardiovascular risk factor: current statusStabilization of high-risk plaquesHypertriglyceridemia and Cardiovascular Diseases: RevisitedLipoprotein apheresis for the treatment of elevated circulating levels of lipoprotein(a): a critical literature reviewOrigin and therapy for hypertriglyceridaemia in type 2 diabetesCardiovascular riskThe Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptorsAtherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Therapeutic approaches to drug targets in atherosclerosis.Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary aTriglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementNiacin: the evidence, clinical use, and future directions.Consensus statement on management of dyslipidemia in Indian subjects.The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The AtheEffect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with DyslipidaemiaThe association of lipoprotein lipase PvuII polymorphism and niacin intake in the prevalence of metabolic syndrome: a KMSRI-Seoul studyA nutrient-dense, high-fiber, fruit-based supplement bar increases HDL cholesterol, particularly large HDL, lowers homocysteine, and raises glutathione in a 2-wk trial.Patient considerations and clinical impact of cholesteryl ester transfer protein inhibitors in the management of dyslipidemia: focus on anacetrapib.Nicotinic acid inhibits hepatic APOA gene expression: studies in humans and in transgenic mice.Reducing vascular events risk in patients with dyslipidaemia: an update for cliniciansLipoprotein (a): a Unique Independent Risk Factor for Coronary Artery Disease.Dietary nutrient intake and metabolic syndrome risk in Chinese adults: a case-control study.Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapyThe Effects of Tetrahydro-iso-alpha Acids and Niacin on Monocyte-Edothelial Cell Interactions and Flow-mediated Vasodilation.Is combined lipid-regulating therapy safe and feasible for the very old patients with mixed dyslipidemia?New evidence for nicotinic acid treatment to reduce atherosclerosis.Important considerations for treatment with dietary supplement versus prescription niacin products.Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review.Extended-release niacin with laropiprant : a review on efficacy, clinical effectiveness and safety.Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes.Pharmacogenomics of lipid-lowering therapies.Demystifying the management of hypertriglyceridaemia.Critical review of non-statin treatments for dyslipoproteinemia.The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory anginaFibrates and niacin: is there a place for them in clinical practice?Extended-release niacin increases anti-apolipoprotein A-I antibodies that block the antioxidant effect of high-density lipoprotein-cholesterol: the EXPLORE clinical trial.Niacin as antidyslipidemic drug.Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism.
P2860
Q24201863-641048D2-45F1-4F75-809A-3172FAE4D3BDQ24623225-F516E940-5B88-437D-9563-06832720AB43Q26738584-66E537EE-BF92-4DF4-9B6E-CD72C434DE42Q26750954-CFCA37DA-1E54-4EE7-9043-BB7C890EFFB4Q26771862-EEAF5A8F-0AAB-4DE7-9C36-BBCCAA951A66Q26824004-ABAD562C-0B5A-4282-B01A-119CEE049604Q26825634-50BC4DBA-C564-42C5-8AE4-DF0DEDCEB5CEQ30486707-7642006F-7AC3-45AB-8A70-FFA9FE1A2334Q33776194-54B6472A-4A4F-4D52-86EB-36ABFB0095C5Q33906710-FE10D8A7-58C9-4268-AEA5-D2A5D01C5CF2Q33948919-3AAF8458-6452-4852-991D-4649342398E2Q34181381-6DAA9311-6C22-4095-A5C2-A2BBF6472369Q34228636-49680BDE-A728-4DA2-8915-3DEF56A3B581Q34980772-9E9234DB-3E5E-41AA-BD9F-10D09C957DF8Q35060328-A488969F-B2B3-4FB8-9A91-A0CE5CFE66ACQ35598833-993D285D-BBB5-4DF8-8598-19D92F202B89Q35863314-224C8BAC-E15F-45ED-8C46-22842092D0C8Q36117465-0763EA22-E3CD-4CBC-B633-8300490F7500Q36197709-F7B4C7FF-FBE5-4987-BDF0-DC5910758E54Q36302760-C56022FC-8BD7-490D-8F5D-9300882F5F26Q36443768-3D3D8091-8429-4C81-B711-BD7DC1185352Q36515765-4F8DA118-733D-4676-9AB2-BE938A21A68CQ37059801-8D736A66-0FAB-4E54-B432-943AA35B8F3AQ37115301-7BF681E1-0A4D-4327-BF76-C8EFFEC0E503Q37323896-229B4D9C-96D6-4CB9-A8F3-72701D4FA1FFQ37466722-FF9B644D-5282-4E38-B676-FB70B9737BF5Q37799365-FFC3845D-A5DD-42BF-AA66-D1C3F129838DQ37862929-6E9AB46E-B940-4ED1-A541-81906F378F7AQ37923968-FABB3936-E521-4A87-8B3A-C37C3426BF41Q37982202-87B52AE4-956E-449F-B5AD-997FD3C66372Q38011204-05DD3B0C-7E64-4168-971C-5171C351BCE4Q38039980-7D054EA4-8B7A-494D-AE82-CB7372329D12Q38112823-03FC34A4-AF09-482C-AE7D-17BFDBF44C6DQ38141575-D2CC0E7E-B0D1-4775-A508-1D100FB56D4DQ38186099-ADF879C4-9DB6-48DE-B100-E1F3C1CAD568Q38233052-153A6A3B-2B0E-4428-95E1-FBF6822A4C79Q38260501-DD4790A4-EAE6-4BB7-8E16-FAC848172619Q38384208-7532A7EF-FE60-4840-B073-1DDB7D29D74EQ38586930-AC8D14C4-1E3E-4658-B5D4-6C4E7088FAC6Q38839105-58D134C0-0042-4E01-8CCA-1B4F6A5EF827
P2860
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk.
description
2010 nî lūn-bûn
@nan
2010 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@ast
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@en
type
label
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@ast
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@en
prefLabel
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@ast
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@en
P2093
P921
P1476
Niacin and fibrates in atherog ...... to reduce cardiovascular risk.
@en
P2093
Jan S Redfern
M John Chapman
Mark E McGovern
Philippe Giral
P304
P356
10.1016/J.PHARMTHERA.2010.01.008
P577
2010-02-11T00:00:00Z